NasdaqGM:OXFD

Stock Analysis Report

Executive Summary

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States.

Snowflake

Fundamentals

Good value with reasonable growth potential.


Similar Companies

Share Price & News

How has Oxford Immunotec Global's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.5%

OXFD

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

-6.2%

OXFD

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: OXFD underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: OXFD underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

OXFDIndustryMarket
7 Day0.5%1.7%2.3%
30 Day8.9%-1.7%-1.0%
90 Day17.0%-1.7%-0.7%
1 Year-6.2%-6.2%11.0%10.1%7.9%5.6%
3 Year18.7%18.7%70.4%65.2%45.6%36.3%
5 Year4.2%4.2%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Oxford Immunotec Global's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oxford Immunotec Global undervalued compared to its fair value and its price relative to the market?

15.88x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate OXFD's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate OXFD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OXFD is good value based on its PE Ratio (15.9x) compared to the Medical Equipment industry average (41.1x).

PE vs Market: OXFD is good value based on its PE Ratio (15.9x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: OXFD is good value based on its PEG Ratio (0.4x)


Price to Book Ratio

PB vs Industry: OXFD is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Oxford Immunotec Global forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

38.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXFD's forecast earnings growth (38% per year) is above the savings rate (2.7%).

Earnings vs Market: OXFD's earnings (38% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: OXFD's revenue (15.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: OXFD's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: OXFD is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Oxford Immunotec Global performed over the past 5 years?

20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: OXFD has become profitable over the past 5 years, growing earnings by 20.9% per year.

Accelerating Growth: OXFD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: OXFD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: OXFD's Return on Equity (11.7%) is considered low.


Return on Assets

ROA vs Industry: OXFD has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: OXFD is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Oxford Immunotec Global's financial position?


Financial Position Analysis

Short Term Liabilities: OXFD's short term assets ($223.3M) exceeds its short term liabilities ($16.7M)

Long Term Liabilities: OXFD's short term assets (223.3M) exceeds its long term liabilities (7.5M)


Debt to Equity History and Analysis

Debt Level: OXFD's debt to equity ratio (0.01%) is considered satisfactory

Reducing Debt: OXFD's debt to equity ratio has reduced from 0.9% to 0.01% over the past 5 years.

Debt Coverage: OXFD's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if OXFD's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: OXFD has a low level of unsold assets or inventory.

Debt Coverage by Assets: OXFD's debt is covered by short term assets (assets are 7444.666660x debt).


Next Steps

Dividend

What is Oxford Immunotec Global's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate OXFD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OXFD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if OXFD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXFD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OXFD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Oxford Immunotec Global's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Peter Wrighton-Smith (45yo)

17.8yrs

Tenure

US$1,617,254

Compensation

Dr. Peter Wrighton-Smith, Ph.D., MEng, Co-founded Oxford Immunotec Limited in 2002 and has been its Chief Executive Officer since its inception. Dr. Wrighton-Smith has been the Chief Executive Officer of O ...


CEO Compensation Analysis

Compensation vs. Market: Peter's total compensation ($USD1.62M) is about average for companies of similar size in the US market ($USD1.82M).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: OXFD's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

4.4yrs

Average Tenure

62yo

Average Age

Experienced Board: OXFD's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Peter Wrighton-Smith (45yo)

    CEO & Executive Director

    • Tenure: 17.8yrs
    • Compensation: US$1.62m
  • Peter Edwardson (57yo)

    Senior VP & Head of Blood Screening

    • Tenure: 2.2yrs
    • Compensation: US$767.47k
  • Jeff Schroeder (58yo)

    President

    • Tenure: 1.8yrs
    • Compensation: US$830.10k
  • Stefan Linn (54yo)

    Chief Operating Officer

    • Tenure: 2.2yrs
    • Compensation: US$840.04k
  • Matt McLaughlin (42yo)

    Chief Financial Officer

    • Tenure: 0.5yrs

Board Members

  • Pat Balthrop (62yo)

    Independent Chairman

    • Tenure: 0.3yrs
    • Compensation: US$106.60k
  • Jim Tobin (74yo)

    Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: US$105.35k
  • Herm Rosenman (72yo)

    Non-Executive Director

    • Tenure: 6yrs
    • Compensation: US$109.60k
  • Dick Sandberg (77yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$150.35k
  • Patricia Randall (69yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$98.68k
  • Mark Klausner

    Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$180.48k
  • Peter Wrighton-Smith (45yo)

    CEO & Executive Director

    • Tenure: 17.8yrs
    • Compensation: US$1.62m
  • Ronnie, Ron Andrews (59yo)

    Non-Executive Director

    • Tenure: 3.9yrs
    • Compensation: US$91.60k
  • Andrew Walton (52yo)

    Non-Executive Director

    • Tenure: 3.9yrs
    • Compensation: US$97.85k
  • Andrew Walton (52yo)

    Non-Executive Director

    • Tenure: 3.9yrs

Company Information

Oxford Immunotec Global PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oxford Immunotec Global PLC
  • Ticker: OXFD
  • Exchange: NasdaqGM
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$412.120m
  • Shares outstanding: 26.83m
  • Website: https://www.oxfordimmunotec.com

Number of Employees


Location

  • Oxford Immunotec Global PLC
  • 143 Park Drive
  • Milton Park
  • Abingdon
  • Oxfordshire
  • OX14 4SE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OXFDNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDNov 2013

Biography

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:17
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.